Fighting Cancer around the World : A Framework for Action
Tackling cancer is a major challenge right on the global level. Europe is only the tip of an iceberg of cancer around the world. Prosperous developed countries share the same problems besetting Europe-and the countries and regions with fewer resources and less propitious conditions are in many cases struggling often heroically against a growing tide of disease. This paper offers a view on these geographically wider, but essentially similar, challenges, and on the prospects for and barriers to better results in this ceaseless battle. A series of panels have been organized by the European Alliance for Personalised Medicine (EAPM) to identify different aspects of cancer care around the globe. There is significant diversity in key issues such as NGS, RWE, molecular diagnostics, and reimbursement in different regions. In all, it leads to disparities in access and diagnostics, patients' engagement, and efforts for a better understanding of cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Healthcare (Basel, Switzerland) - 10(2022), 11 vom: 25. Okt. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Revised 26.11.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/healthcare10112125 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348740549 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348740549 | ||
| 003 | DE-627 | ||
| 005 | 20231226040949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/healthcare10112125 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348740549 | ||
| 035 | |a (NLM)36360466 | ||
| 035 | |a (PII)2125 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Horgan, Denis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fighting Cancer around the World |b A Framework for Action |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Tackling cancer is a major challenge right on the global level. Europe is only the tip of an iceberg of cancer around the world. Prosperous developed countries share the same problems besetting Europe-and the countries and regions with fewer resources and less propitious conditions are in many cases struggling often heroically against a growing tide of disease. This paper offers a view on these geographically wider, but essentially similar, challenges, and on the prospects for and barriers to better results in this ceaseless battle. A series of panels have been organized by the European Alliance for Personalised Medicine (EAPM) to identify different aspects of cancer care around the globe. There is significant diversity in key issues such as NGS, RWE, molecular diagnostics, and reimbursement in different regions. In all, it leads to disparities in access and diagnostics, patients' engagement, and efforts for a better understanding of cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a diagnostics | |
| 650 | 4 | |a genomics | |
| 650 | 4 | |a global | |
| 650 | 4 | |a health care | |
| 650 | 4 | |a liquid biopsy | |
| 650 | 4 | |a next-generation sequencing | |
| 650 | 4 | |a patients | |
| 650 | 4 | |a personalized medicine | |
| 650 | 4 | |a policy framework | |
| 650 | 4 | |a reimbursement | |
| 700 | 1 | |a Mia, Rizwana |e verfasserin |4 aut | |
| 700 | 1 | |a Erhabor, Tosan |e verfasserin |4 aut | |
| 700 | 1 | |a Hamdi, Yosr |e verfasserin |4 aut | |
| 700 | 1 | |a Dandara, Collet |e verfasserin |4 aut | |
| 700 | 1 | |a Lal, Jonathan A |e verfasserin |4 aut | |
| 700 | 1 | |a Domgue, Joel Fokom |e verfasserin |4 aut | |
| 700 | 1 | |a Ewumi, Oladimeji |e verfasserin |4 aut | |
| 700 | 1 | |a Nyawira, Teresia |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Salomé |e verfasserin |4 aut | |
| 700 | 1 | |a Kondji, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Francisco, Ngiambudulu M |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Sadakatsu |e verfasserin |4 aut | |
| 700 | 1 | |a Chuah, Chai |e verfasserin |4 aut | |
| 700 | 1 | |a De Guzman, Roselle |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Anupriya |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy Nallamalla, Krishna |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Woong-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathi, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathi, Ravikant |e verfasserin |4 aut | |
| 700 | 1 | |a Johns, Amber |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Mohan P |e verfasserin |4 aut | |
| 700 | 1 | |a Phipps, Maude E |e verfasserin |4 aut | |
| 700 | 1 | |a Dube, France |e verfasserin |4 aut | |
| 700 | 1 | |a Whittaker, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherji, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Rasheed, Hadi Mohamad Abu |e verfasserin |4 aut | |
| 700 | 1 | |a Kozaric, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Joseph A |e verfasserin |4 aut | |
| 700 | 1 | |a Doral Stefani, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Augustovski, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Aponte Rueda, Maria Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita Alarcon, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Barrera-Saldana, Hugo A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Healthcare (Basel, Switzerland) |d 2013 |g 10(2022), 11 vom: 25. Okt. |w (DE-627)NLM253742684 |x 2227-9032 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:11 |g day:25 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/healthcare10112125 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 11 |b 25 |c 10 | ||